Annual Report

Overview

The report records consolidated 2025 revenue of RMB31,629,416 thousand and highlights a 13.0% year-on-year increase. It describes 28 self-developed innovative molecules reaching clinical stage and seven Class 1 innovative drugs obtaining marketing approval during the Reporting Period. The Group ended the year with 20,602 employees.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Publication date: 25 March 2026
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services